Project Grant R24OD040592
- Federal Grant Award Summary The Oklahoma Medical Research Foundation (OMRF) received a $426,250 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded on August 15, 2025, with a completion date of July 31, 2030. The grant supports fundamental research investigating novel pathways in heterochromatin regulation, specifically examining how different chromatin regulatory complexes control...
- Federal Project Grant Award Summary The Oklahoma Medical Research Foundation (OMRF) received a $787,710 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) effective September 1, 2025, with a completion date of August 31, 2027. This award funds fundamental research investigating the function and regulation of DNA replication origin firing factors, specifically focusing on the recruitment and...
- Federal Project Grant Award Summary The Oklahoma Medical Research Foundation (OMRF) received a $937,750 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective August 8, 2025 through May 31, 2030. This award funds fundamental biomedical research investigating the regulation of gene transcription and DNA replication by chromatin readers from the bromodomain and extra-terminal domain...
- This federal Project Grant award of $999,999.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the Oklahoma Medical Research Foundation's (OMRF) research to elucidate the impact of IFIH1 during systemic lupus erythematosus. The award, which runs from May 1, 2025 to April 30, 2028, enables OMRF, a non-profit biomedical research institute, to conduct advanced scientific investigations in this critical autoimmune disease...
- Federal Grant Award Summary Old Dominion University received an $880,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), with an award date of August 15, 2025, and completion date of April 30, 2030. The research project, titled "Deciphering the Role of RNA Modifications in Maternal mRNA Clearance," investigates fundamental mechanisms of how RNA modifications regulate the...
- Federal Grant Award Summary The University of Oklahoma Health Sciences Center (OUHSC) received a $2,129,950 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded on May 1, 2026, with a completion date of January 31, 2031. The grant funds the Oklahoma Center for Biomedical Research Excellence in Sensory Biology (OCBRESB), a multidisciplinary center of excellence designed to advance...
- Federal Project Grant Award Summary The National Institutes of Health (NIH) Office of the Director awarded $230,250 through the Research Infrastructure Programs (CFDA 93.351) to the University of Nebraska Medical Center for the development of transgenic mouse model resources expressing red fluorescence-based genetically encoded indicators. This two-year project, which commenced July 1, 2025 and concludes June 30, 2027, addresses critical limitations of existing green fluorescent protein...
- Federal Grant Award Summary The University of Oklahoma Health Sciences Center (OUHSC) received a $1,140,592 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective July 1, 2025, through June 30, 2030. This award supports the "Learning and Achievement in Biomedical Sciences" training initiative, which addresses Oklahoma's public health challenges—including high rates of obesity,...
- Federal Grant Award Summary The University of Oklahoma received a $2.55 million Project Grant from the National Institute of General Medical Sciences under the Biomedical Research and Research Training program (CFDA 93.859) to establish the Oklahoma Center of Immunoengineering (OCIE). The award, effective May 15, 2026, through January 31, 2031, supports the creation of a sustainable research infrastructure and network that consolidates currently dispersed immunoengineering and omics data science...
- Federal Project Grant Award Summary The Oklahoma Medical Research Foundation (OMRF) received a $2.43 million Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 3, 2025, with completion scheduled for August 31, 2029. This award funds investigator-initiated biomedical research aimed at resolving the mechanisms by which the IFIH1 risk variant (RS1990760) contributes to...
The Oklahoma Medical Research Foundation (OMRF) received a $805,745 Project Grant from the National Institutes of Health Office of the Director under the Research Infrastructure Programs (CFDA 93.351) to develop precision genome editing tools for functional characterization of genetic variants. The award, effective July 1, 2026 through March 31, 2030, supports the establishment of a high-throughput, cost-effective platform for in vivo functional validation of human disease-associated genetic variants using zebrafish as a model organism. This initiative addresses the significant clinical challenge posed by variants of uncertain significance (VUS), which currently account for over half of genetic variants identified through clinical sequencing and impede accurate genetic diagnosis and patient care. OMRF will deliver three integrated products and services: (1) high-fidelity base editors with expanded genomic targeting capabilities to model single-nucleotide variants with minimal off-target mutations; (2) a deep learning computational model optimized for zebrafish to design guide ribonucleic acids for clustered regularly interspaced short palindromic repeats (CRISPR) base editing; and (3) next-generation prime and click editors for precise in vivo editing. The platform is designed to overcome current limitations in specificity and scalability of existing genome editing methods, thereby accelerating variant interpretation, reducing diagnostic delays, and supporting therapeutic development across aquatic disease models.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $805.7k | 6/19/26 |